Medical/Pharmaceuticals

Syneron Bio Announces Completion of $150 Million Series B Financing

BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Dechen...

2026-04-03 15:02 4562

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with ulcerative c...

2026-04-02 19:00 5871

StairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent

SHANGHAI, April 2, 2026 /PRNewswire/ -- Shanghai StairMed Technology Co., Ltd. ("StairMed" or "the Company") recently announced the closing of a strategic financing round totaling RMB 500 million. The round was led by Alibaba, with strong continued participation from existing shareholders includi...

2026-04-02 14:41 4007

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions

* Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions. * The presentation will be delivered by W. Timothy Garvey, MD, a g...

2026-04-02 12:04 7507

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases - - BBT001 achieved rapid, deep, a...

2026-04-01 21:00 7659

Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals

HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Ev...

2026-04-01 18:30 4474

Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that  its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan Drug Desig...

2026-04-01 10:02 5791

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...

2026-03-31 22:00 5883

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agree...

2026-03-31 21:00 4687

Co-PSMA data published in the European Urology journal

SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...

2026-03-31 20:58 4929

Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading

Public offering oversubscribed 1,073 times as medical imaging AI company debuts on HKEX HANGZHOU, China, March 31, 2026 /PRNewswire/ -- Hangzhou Diagens Biotechnology Co., Ltd. (HKEX: 02526) today began trading on the Main Board of The Stock Exchange of Hong Kong. Shares closed at HK$202.60, up ...

2026-03-31 18:34 5971

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's...

2026-03-31 17:40 4520

Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children

SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced thatthe U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-...

2026-03-31 14:10 4961

NAVER D2SF Makes Follow-On Investment in Soundable Health, an AI-Driven Health Tech Startup Scaling in the U.S. Market

SEOUL, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Soundable Health, a health tech startup leveraging AI-powered acoustic analysis to enable clinical-grade diagnostics through everyday devices. Having parti...

2026-03-31 08:30 5451

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...

2026-03-31 08:00 5161

Sanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence

SHANGHAI, March 30, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals has recently been honored as a "Shanghai Municipal Enterprise Technology Center" in recognition of its outstanding technological innovation capabilities, comprehensive R&D infrastructure, sustained investment in innovation, and r...

2026-03-30 22:00 6888

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today a...

2026-03-30 21:53 9973

Tigermed Announces 2025 Annual Results

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2026-03-30 20:56 6934

EDAN Launches EDAN Nano OB Assist, an AI-Enabled Handheld Ultrasound, to Expand Access to Prenatal Screening in Africa

NAIROBI, Kenya, March 30, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a global medical device company, announced the launch of EDAN Nano OB Assist, an AI-enabled handheld ultrasound system designed to expand access to essential prenatal screening in ...

2026-03-30 20:55 4439

CELEBRATING 25 YEARS AND BEYOND OF LIFE AFTER ORGAN TRANSPLANTATION AT THE NATIONAL UNIVERSITY CENTRE FOR ORGAN TRANSPLANTATION

Honouring 35 patients who stand as inspiring examples of resilience, underscoring the long-term success of organ transplantation SINGAPORE, March 30, 2026 /PRNewswire/ -- For transplant recipients, reaching the 25-year mark is a significant achievement. According to international statistics, a d...

2026-03-30 19:43 4804
1 ... 17181920212223 ... 261

Week's Top Stories